Metabolic Symbiosis Enables Adaptive Resistance to Anti-angiogenic Therapy that Is Dependent on mTOR Signaling.
about
Personalising and targeting antiangiogenic resistance: a complex and multifactorial approach.Radiosynthesis and validation of (±)-[18F]-3-fluoro-2-hydroxypropionate ([18F]-FLac) as a PET tracer of lactate to monitor MCT1-dependent lactate uptake in tumorsRapamycin (mTORC1 inhibitor) reduces the production of lactate and 2-hydroxyglutarate oncometabolites in IDH1 mutant fibrosarcoma cellsFrom Krebs to clinic: glutamine metabolism to cancer therapy.Annual Meeting of the International Society of Cancer Metabolism (ISCaM): Metabolic Networks in CancerStroma-derived HGF drives metabolic adaptation of colorectal cancer to angiogenesis inhibitorsRacial disparity in metabolic regulation of cancer.Targeting Metabolic Symbiosis to Overcome Resistance to Anti-angiogenic Therapy.The acceleration of glucose accumulation in renal cell carcinoma assessed by FDG PET/CT demonstrated acquisition of resistance to tyrosine kinase inhibitor therapy.Resistance to mTORC1 Inhibitors in Cancer Therapy: From Kinase Mutations to Intratumoral Heterogeneity of Kinase ActivityMathematical modeling links Wnt signaling to emergent patterns of metabolism in colon cancer.The matricellular protein CYR61 promotes breast cancer lung metastasis by facilitating tumor cell extravasation and suppressing anoikis.Imaging Tumor Metabolism to Assess Disease Progression and Treatment Response.Trimming the Vascular Tree in Tumors: Metabolic and Immune Adaptations.Anti-angiogenesis target therapy for advanced osteosarcoma (Review).Microenvironmental regulation of tumour angiogenesis.Metabolic Interactions in the Tumor Microenvironment.Resistance to Antiangiogenic Therapies by Metabolic Symbiosis in Renal Cell Carcinoma PDX Models and Patients.Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation.Antiangiogenic resistance via metabolic symbiosis.Up-regulation of miR-497 confers resistance to temozolomide in human glioma cells by targeting mTOR/Bcl-2.ROS and radiotherapy: more we care.Lactate stimulates CA IX expression in normoxic cancer cells.Targeting HIF-1α/PDK1 Axis by Dichloroacetate (DCA) Suppresses Bleomycin-induced Pulmonary Fibrosis.Monocarboxylate transporter 1 (MCT1), a tool to stratify acute myeloid leukemia (AML) patients and a vehicle to kill cancer cells.Tumour acidosis: from the passenger to the driver's seat.Contribution of Adipose Tissue to Development of Cancer.Mitochondrial Metabolism: Yin and Yang for Tumor Progression.Fatty acid synthase (FASN) as a therapeutic target in breast cancer.Interruption of lactate uptake by inhibiting mitochondrial pyruvate transport unravels direct antitumor and radiosensitizing effects.mTOR at the Transmitting and Receiving Ends in Tumor Immunity.The role of tumor microenvironment in resistance to anti-angiogenic therapy.Influence of the Tumor Microenvironment on Cancer Cells Metabolic Reprogramming.Flt3 Regulation in the Mononuclear Phagocyte System Promotes Ocular Neovascularization.p53 and metabolism: from mechanism to therapeutics.Mitochondrial metabolism and cancer
P2860
Q33639714-B27F3809-A7C0-4A32-BFFE-DCE653C4931FQ33648519-F22FE640-2AF1-4130-9F33-EF82A39DF7ECQ33759313-0868C3CF-DB17-4C57-B15E-98BE847F57D0Q33834498-55093858-768A-4E78-9034-32AC66C22FAFQ33869480-D88B120C-03EE-4DAF-86E9-DF04A0F0FC7FQ33888739-41679545-73CB-4B96-A15D-084A771E2F50Q33906704-EF7D97A0-89C7-4EA3-B3D7-1C19F7B9BE50Q36910309-EE8CE638-9E7C-4A39-8EEF-CEF81C3766ADQ37576212-B5EE6F89-C2C1-4449-ABC0-100C49ECC830Q37661161-18E391BD-507E-494D-B7A9-CD18B23F9072Q37668798-D7D45FED-8807-4E45-892E-AF7FE1475312Q37705939-1BA14F82-7D0E-42A3-9127-8ADA24730548Q38949887-DBEBA7AA-AA86-4378-A7B9-CCEE4F9CFA6EQ39232954-DE5E4718-C792-443C-BAF0-D64FEF0EDF76Q39401628-AB075275-8062-49A1-865C-A07B217315D8Q39433862-A2AFEFFF-CF7D-4E62-9D34-B39F5C3972E9Q39452100-47E33C66-8D94-4472-8B28-77DFB8A6AF34Q39805218-67D4C6B1-6316-4312-A082-88E33B1A19CEQ41369903-60B216DD-9C00-4703-8C97-77076F715D8EQ41487795-DC227BB3-1942-4449-BADB-8CEE140150A5Q41995095-5E4132A4-7E0C-43FE-A728-FD5FE83D3108Q42335078-4740151C-B07D-49D6-B111-BCCF8CAA9614Q46269325-46641EE7-3C61-463B-A265-956DCBF3B5E5Q46792366-E34D320D-3612-4D56-BC6D-E5BDD409C16CQ47111427-4050DF85-F8F8-4761-B4DC-58CE5EB3070AQ47772621-AD8CCDCB-A71C-46C2-A1FB-3F6113ABAD5DQ49164235-7FAC3B4F-9E26-43CB-A24E-52BC8AF72DF4Q49918002-59DC1EFA-70EE-47FE-AC9C-520487E38C60Q50044384-796FE2A9-4E5A-46AE-AA92-EB18947F9D38Q51735722-5F57715D-A037-41CF-A980-7A023C40996EQ52319565-3EBBD2FC-DDF8-4075-A80E-2C831698BE72Q52645823-E46C012A-6D13-4CD0-A3B7-5ADF22AB6E80Q54945775-BB67F0CC-84A2-4596-930C-A21F61EB1257Q54977469-23FE4FE1-7377-40DC-B09D-B187339B3F6DQ55002919-6FF47EA0-CE4D-47E0-AFC0-A4DE64B1D366Q57842307-01B2F904-33AE-46EE-84B5-D2E46C07F7A0
P2860
Metabolic Symbiosis Enables Adaptive Resistance to Anti-angiogenic Therapy that Is Dependent on mTOR Signaling.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Metabolic Symbiosis Enables Ad ...... s Dependent on mTOR Signaling.
@en
type
label
Metabolic Symbiosis Enables Ad ...... s Dependent on mTOR Signaling.
@en
prefLabel
Metabolic Symbiosis Enables Ad ...... s Dependent on mTOR Signaling.
@en
P2093
P2860
P1433
P1476
Metabolic Symbiosis Enables Ad ...... s Dependent on mTOR Signaling.
@en
P2093
Carmen M Warren
Douglas Hanahan
Elizabeth Allen
Mei-Wen Peng
Pascal Miéville
Sadegh Saghafinia
P2860
P304
P356
10.1016/J.CELREP.2016.04.029
P577
2016-04-27T00:00:00Z